Apoe Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Full Name | Apolipoprotein E |
|---|
| Chromosomal Location | 19q13.32 |
|---|
| NCBI Gene ID | 348 |
|---|
| OMIM | 107741 |
|---|
| Ensembl ID | ENSG00000130203 |
|---|
| UniProt | P02649 |
|---|
| Associated Diseases | Alzheimer's Disease, Hyperlipoproteinemia, Atherosclerosis |
|---|
APOE (Apolipoprotein E), located on chromosome 19q13.32, encodes a 299-amino acid lipid transport protein that is critical for lipid metabolism in the brain and periphery[^1]. APOE is the most significant genetic risk factor for late-onset Alzheimer's disease (AD), with the APOE4 allele increasing risk by 3-4 fold in heterozygotes and 12-15 fold in homozygotes[^2]. APOE is primarily produced by astrocytes in the brain but is also expressed by microglia and neurons under stress conditions, where it plays essential roles in lipid transport, synaptic plasticity, and neuroinflammation[^3].
The APOE gene encodes apolipoprotein E (ApoE), a 299-amino acid lipid transport protein:
- Lipid transport: Primary apolipoprotein in brain; mediates cholesterol and phospholipid transport between cells.
- Lipoprotein metabolism: Component of chylomicrons, VLDL, and HDL-like particles.
- Neuronal repair: Required for injury response and neuronal membrane maintenance.
- Synaptic plasticity: Regulates synaptic function, spine density, and long-term potentiation.
- Aβ metabolism: Binds to amyloid-beta (Aβ) and influences its clearance, aggregation, and deposition.
- Neuroinflammation: Modulates microglial activation, cytokine production, and inflammatory responses.
- Tau pathology: Associates with neurofibrillary tangles in AD brain; influences tau phosphorylation and spreading.
- Blood-brain barrier: Regulates BBB integrity and function.
ApoE is produced primarily by astrocytes in the brain, but also by microglia and neurons under stress. It exists in multiple isoforms (ApoE2, ApoE3, ApoE4) that differ in amino acid positions 112 and 158, leading to distinct structural and functional properties.
| Feature |
Details |
| Molecular weight |
~34 kDa |
| Structure |
N-terminal domain (receptor binding) + C-terminal domain (lipid binding) |
| Isoforms |
ApoE2 (Cys112, Cys158), ApoE3 (Cys112, Arg158), ApoE4 (Arg112, Arg158) |
| Receptor binding |
LDLR, LRP1, HSPG |
| Lipid binding |
C-terminal domain |
- Risk factor: APOE4 is the strongest genetic risk factor for late-onset AD.
- Mechanism: Multiple mechanisms including:
- Impaired Aβ clearance and enhanced aggregation
- Increased neuroinflammation
- Synaptic dysfunction
- Tau pathology acceleration
- Vascular dysfunction
- Mitochondrial impairment
| Isoform |
AD Risk |
Function |
| APOE2 |
Protective |
Normal/enhanced Aβ clearance |
| APOE3 |
Intermediate |
Normal function |
| APOE4 |
Increased risk |
Impaired Aβ clearance, gain of toxic function |
- APOE4 homozygotes: 12-15x increased AD risk; earlier onset (mean ~68 years).
- APOE4 heterozygotes: 3-4x increased AD risk; mean onset ~75 years.
- APOE2 carriers: May have delayed onset; some protection.
- Cardiovascular disease: APOE4 associated with elevated LDL cholesterol and atherosclerosis.
- Multiple Sclerosis: APOE4 associated with more severe disease.
- Traumatic brain injury: APOE4 worsens outcomes.
- Stroke: APOE4 increases risk and worsens outcomes.
- FTD: Some association with specific APOE genotypes.
- Primary source: Astrocytes (brain), liver (periphery).
- Cellular localization: Secreted, associates with lipoproteins.
- Regional specificity: High in cortex, hippocampus, basal forebrain.
- Cell types: Astrocytes, microglia, neurons (under stress).
- Regulation: Upregulated in AD brain; influenced by aging and injury.
- Gene therapy: AAV-APOE2 delivery to CNS in clinical trials.
- Small molecules: ApoE-directed compounds in development.
- Peptide mimetics: ApoE4-specific targeting.
- Anti-Aβ antibodies: Effectiveness varies by APOE genotype.
- Aβ aggregation inhibitors: May benefit APOE4 carriers.
- Vaccination: APOE4 carriers show different response to Aβ vaccines.
- Anti-inflammatory: Targeting APOE4-driven neuroinflammation.
- Synaptic support: Enhancing synaptic function in APOE4 carriers.
- Vascular protection: Addressing cerebrovascular contributions.
- Apoe knockout: Viable, but show lipid metabolism defects.
- APOE4 knock-in: Reproduces human isoform effects.
- APOE4 + amyloid: Synergistic effects on pathology.
- Targeted replacement mice: Express human APOE isoforms.
- APOE4 drives Aβ accumulation in mice.
- APOE4 impairs synaptic plasticity.
- Microglial responses differ by isoform.
- Vascular dysfunction with APOE4.
- Corder EH, et al. (1993). "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families." Science. PMID:8346443
- Liu CC, et al. (2013). "Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy." Nat Rev Neurol. PMID:23314233
- Huang Y, et al. (2015). "Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3." J Alzheimers Dis. PMID:25540902
- Koffie RM, et al. (2012). "Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta." Brain. PMID:22492800
- Verghese PB, et al. (2013). "ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions." Proc Natl Acad Sci USA. PMID:23431167
- Mahley RW, et al. (2006). "Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders." J Mol Med. PMID:16651862
- Holtzman DM, et al. (2012). "Apolipoprotein E facilitates Alzheimer's disease pathology and cognitive decline." Nat Rev Neurosci. PMID:23269430
- Bell RD, et al. (2012). "Apolipoprotein E4 allele: effects on brain and circulation." Nat Rev Neurosci. PMID:23269431
The study of Apoe Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
- 1 Mahley RW. (1988). "Apolipoprotein E: cholesterol transport protein with expanding role in cell biology." Science. PMID:3283935.
- 2 Corder EH, et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease. Science. PMID:8346443.
- 3 Liu CC, et al. (2013). Apolipoprotein E and Alzheimer disease. Nat Rev Neurol. PMID:23314233.
- 4 Huang Y, et al. (2015). Apolipoprotein E and Alzheimer's disease. J Alzheimers Dis. PMID:25540902.
- 5 Koffie RM, et al. (2012). Apolipoprotein E4 effects in Alzheimer's disease. Brain. PMID:22492800.
- 6 Verghese PB, et al. (2013). ApoE influences amyloid-beta clearance. Proc Natl Acad Sci USA. PMID:23431167.
- 7 Holtzman DM, et al. (2012). Apolipoprotein E facilitates Alzheimer's disease pathology. Nat Rev Neurosci. PMID:23269430.
- 8 Bell RD, et al. (2012). Apolipoprotein E4 allele: effects on brain and circulation. Nat Rev Neurosci. PMID:23269431.
-